If αvβ3, coexisting with CD47 on the surface of cancer cells, regulates the CD47–SIRPα immune checkpoint, then an immune checkpoint therapy that specifically interferes with CD47/αvβ3 interactions on cancer cells should avoid side effects on red blood cells, which do not express αvβ3, unlike CD47 antibodies that target CD47 alone.[37, 38] Furthermore, specifically targeting the interfaces that determine CD47/αvβ3 interactions on cancer cells is expected to have fewer side effects compared to targeting CD47 or αvβ3 alone. This evidence concerns the gene CD47 and cancer.